Posted by rina on September 11, 2007, at 17:07:18
In reply to Re: Lyrica (pregabalin) Reports other than jlbl2l?, posted by Toothy on September 9, 2007, at 20:53:53
Hi,
I found a little bit of information that might be helpful. If not, sorry for rambling. Good Luck from one psychobabbler to another...lolCLINICAL STUDIES WITH LYRICA (PREGABALIN) IN NEUROPATHIC PAIN AND ANXIETY DISORDER
Data from a series of phase II and III placebo-controlled clinical studies in over 1,200 patients with generalised anxiety disorder suggest that Lyrica (pregabalin) will be effective for this disabling disorder. In comparison with venlafaxine, pregabalin provided more rapid relief of psychic and somatic symptoms.
In comparison with alprazolam (a benzodiazepine), Lyrica (pregabalin) appeared equally effective in reducing somatic symptoms. Overall, these findings show that Lyrica (pregabalin) combines the benefits of both antidepressants and benzodiazepines. It appears at least as rapid as benzodiazepines against somatic symptoms, while providing more rapid control of psychic symptoms than antidepressants.
MARKETING COMMENTARY
Once generic manufacture of gabapentin is approved, sales of Pfizer's Neurontin are likely to fall dramatically. Encouraging physicians to switch patients from Neurontin to Lyrica (pregabalin), if approved, will be an important strategy in minimising the impact of generic competition.
Lyrica (pregabalin) is as effective as Neurontin, but at lower doses, which translates to fewer side effects. Thus, it is well placed to capture Neurontin's market share. Through the successful launch of follow-on products, Pfizer has maintained leadership in other CNS areas, such as the market for antidepressants.
http://www.drugdevelopment-technology.com/projects/pregabalin/Pregabalin (Lyrica) Helped Anxiety:
In a 4-week DB PC study of 276 adults with generalized anxiety disorder, pregabalin (150 mg/day or 600 mg/day), lorazepam (6 mg/day), or placebo. Fewer patients given lorazepam (59%) completed the trial than placebo (73%), 600 mg/day of pregabalin (71%), or 150 mg/day of pregabalin (90%).
Hamilton anxiety scores decreased 9.2 with150 mg/day of pregabalin, 10.3 with 600 mg/day of pregabalin and 12.0 with lorazepam vs. 6.8 for placebo. There were no serious adverse events reported by patients given pregabalin, and no withdrawal syndrome was associated with pregabalin treatment. Pregabalin in generalized anxiety disorder: a placebo-controlled trial by Pande AC, Crockatt JG, et al. Am J Psychiatry 2003 Mar;160(3):533-40. Ed: Pfizer is developing this new medication.
poster:rina
thread:414879
URL: http://www.dr-bob.org/babble/20070911/msgs/782267.html